Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma

被引：8
|
作者：
Khodadoust, Michael S.
Feldman, Tatyana A.
Yoon, Dok Hyun
Yannakou, Costas K.
Radeski, Dejan
Kim, Youn H.
Mehta-Shah, Neha
Khot, Amit
Wilcox, Ryan A.
Kim, Won Seog
Horwitz, Steven M.
Buggy, Joseph J.
Hotson, Andrew
Hill, Craig M.
Munneke, Brian
Mahabhashyam, Suresh
Miller, Richard A.
Janc, James W.
Mobasher, Mehrdad
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-137782
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Interleukin-2-inducible T-cell kinase inhibition to block NF-κB signaling exerts anti-tumor effects and enhances chemotherapy in NK/ T-cell lymphoma
    Cao, Jiaowu
    Hu, Dingyao
    Yu, Hui
    Xie, Yan
    Mi, Lan
    Ye, Yingying
    Deng, Mi
    Zhang, Weimin
    Li, Miaomiao
    Wang, Dedao
    Qi, Fei
    Wu, Jiajin
    Song, Yuqin
    Zhu, Jun
    Ding, Ning
    CANCER LETTERS, 2025, 618
  • [22] Interleukin-2-inducible T-cell kinase expression and relation to disease severity in systemic lupus erythematosus
    Xu, Wang-Dong
    Su, Lin-Chong
    Xie, Qi-Bing
    Zhao, Yi
    Liu, Yi
    CLINICA CHIMICA ACTA, 2016, 463 : 11 - 17
  • [23] All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma
    Fante, Matthias A.
    Harrer, Dennis C.
    Zartner, Barbara
    Lueke, Florian
    Mayer, Stephanie
    Menhart, Karin
    Reichle, Albrecht
    Herr, Wolfgang
    Vogelhuber, Martin
    Heudobler, Daniel
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [24] Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT
    Mammadli, Mahinbanu
    Huang, Weishan
    Harris, Rebecca
    Sultana, Aisha
    Cheng, Ying
    Tong, Wei
    Pu, Jeffery
    Gentile, Teresa
    Dsouza, Shanti
    Yang, Qi
    Bah, Alaji
    August, Avery
    Karimi, Mobin
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [25] Interleukin-2-Inducible T-Cell Kinase Deficiency-New Patients, New Insight? (vol 9, 979, 2018)
    Ghosh, Sujal
    Drexler, Ingo
    Bhatia, Sanil
    Adler, Heiko
    Gennery, Andrew R.
    Borkhardt, Arndt
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [26] Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694
    Zhong, Yiming
    Dong, Shuai
    Strattan, Ethan
    Ren, Li
    Butchar, Jonathan P.
    Thornton, Kelsey
    Mishra, Anjali
    Porcu, Pierluigi
    Bradshaw, J. Michael
    Bisconte, Angelina
    Owens, Timothy D.
    Verner, Erik
    Brameld, Ken A.
    Funk, Jens Oliver
    Hill, Ronald J.
    Johnson, Amy J.
    Dubovsky, Jason A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (10) : 5960 - 5978
  • [27] Molecular Characteristics of CTA056, a Novel Interleukin-2-Inducible T-Cell Kinase Inhibitor that Selectively Targets Malignant T Cells and Modulates Oncomirs
    Guo, Wenchang
    Liu, Ruiwu
    Ono, Yoko
    Ma, Ai-Hong
    Martinez, Anthony
    Sanchez, Eduardo
    Wang, Yan
    Huang, Wenzhe
    Mazloom, Anisha
    Li, Jixian
    Ning, Jinying
    Maverakis, Emanual
    Lam, Kit S.
    Kung, Hsing-Jien
    MOLECULAR PHARMACOLOGY, 2012, 82 (05) : 938 - 947
  • [28] Interleukin-2-Inducible T-Cell Kinase Deficiency Impairs Early Pulmonary Protection Against Mycobacterium tuberculosis Infection
    Huang, Lu
    Ye, Kaixiong
    McGee, Michael C.
    Nidetz, Natalie F.
    Elmore, Jessica P.
    Limper, Candice B.
    Southard, Teresa L.
    Russell, David G.
    August, Avery
    Huang, Weishan
    FRONTIERS IN IMMUNOLOGY, 2020, 10
  • [29] A negative role for the interleukin-2-inducible T-cell kinase (ITK) in human Foxp3+ TREG differentiation
    Mamontov, Polina
    Eberwine, Ryan A.
    Perrigoue, Jackie
    Das, Anuk
    Friedman, Joshua R.
    Mora, J. Rodrigo
    PLOS ONE, 2019, 14 (04):
  • [30] Regulation of Cx43 Gap Junction Intercellular Communication by Bruton's Tyrosine Kinase and Interleukin-2-Inducible T-Cell Kinase
    Basu, Ishika
    Li, Hanjun
    Trease, Andrew J.
    Sorgen, Paul L.
    BIOMOLECULES, 2023, 13 (04)
12345